Spring 2023

An illustration with a colorful blue-red gradient has curving shapes representing the flow of time with icons representing cells, DNA, molecules, a syringe, etc.

Why Medical Advancements at Penn Power FDA Approved Treatments

Since 2017, the FDA has approved more than two dozen new therapies with roots at Penn Medicine — almost half of which are first-in-class for their indications. Becoming a hub for drug research and development took a lot more than luck.

The Pennovation Center, a wide brick building with angular glass shapes jutting from one end and the word “Pennovation” in large letters above the roofline.

The Path from Innovation to Implementation

Penn’s infrastructure in both supporting clinical research and forging commercial partnerships smooths the way from ideas to FDA-approved therapies.

Sunil Singhal, MD, examines lung tissue during a surgical procedure using a glowing tumor agent, while a colleague observes.

Why New Cancer Treatment Discoveries are Proliferating

There are fewer cancer deaths and more cancer therapies than ever, in part because scientists now design drugs to attack cancer based on its biology.

Curving shapes on a red/blue gradient background with icons indicating drugs, populations, and outreach.

Putting Biomedical Research Advances Within Reach

While driving biomedical innovation and new therapies, Penn pushes for equity to make vaccines and treatments available and accessible to more people.

Can We Intercept Cancer? A New Frontier in Cancer Research

It’s not prevention or therapy. Penn Medicine researchers are at the forefront of new scientific efforts to interrupt the development of cancer at its earliest stages.
PennHealthX: At the Crossroads of Medicine, Business & Tech

PennHealthX has grown, like an entrepreneurial startup itself, to become an influential student-driven creative hub for projects and programs at the intersection of medicine with other disciplines.
How Penn Medicine is Serving a Changing World

Penn Medicine is a place where we make breathtaking discoveries and put them to work.
A Port in the Storm

Dr. David Fajgenbaum’s research into a deadly cytokine condition has broad implications for Castleman disease, COVID-19, and more.
Seeing Penn Through New Eyes

Alumnus Dr. Bennie Jeng returns to Penn as the new chair of Ophthalmology and director of the Scheie Eye Institute.
Penn Medicine and Wharton Invest for Public Health Impact

Investing in startup businesses is one of the newest ways Penn is answering that call to serve the community’s health needs through the Fund for Health.
Decades in Pursuit of a Diabetes Cure

Penn scientists and colleague worldwide are investigating islet cell transplantation as a potential diabetes cure.
Penn Hematology/Oncology Enters its Next Chapter

Alison Loren, MD, the new division chief, shares reflections on leadership that involve thinking broadly and inclusively.
Very Personal Care — Made Possible By Very Personal Philanthropy

Sweet syndrome looks and responds differently for each patient, requiring constant innovation and creativity. A family’s personal connection and philanthropy has inspired recent progress that made a big difference for one patient.
Growing a Penn Med Family Bound by Service

The McCracken/MacCracken (McMac) Student Travel Award for Indigenous Health provides financial assistance to two final-year Perelman School of Medicine students’ experiential learning at Indigenous health sites in the U.S.